We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.14B
AUM Growth
+$264M
Cap. Flow
+$471M
Cap. Flow %
15.02%
Top 10 Hldgs %
65.37%
Holding
91
New
20
Increased
10
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$159M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$94.1M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$83.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$61.6M
5
TSVT
2seventy bio
TSVT
+$59.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$82.1M
2
STTK icon
Shattuck Labs
STTK
+$75.6M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$25.2M
4
NRIX icon
Nurix Therapeutics
NRIX
+$24.8M
5
BLUE
bluebird bio
BLUE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMPMW
76
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$327K 0.01%
33,333
– –
BCAB icon
77
BioAtla
BCAB
$5.34M
– –
-1,000
Closed -$1.47M
BLUE
78
DELISTED
bluebird bio
BLUE
– –
-61,954
Closed -$15.3M
BPMC
79
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-250,000
Closed -$25.9M
CRVS icon
80
Corvus Pharmaceuticals
CRVS
$1.1B
– –
-2,081,077
Closed -$10.1M
CYCN icon
81
Cyclerion Therapeutics
CYCN
$15.2M
– –
-80,314
Closed -$4.93M
IGMS
82
DELISTED
IGM Biosciences
IGMS
– –
-38,030
Closed -$2.5M
MGTX icon
83
MeiraGTx Holdings
MGTX
$1.08B
– –
-94,819
Closed -$1.25M
SRRK icon
84
Scholar Rock
SRRK
$5.88B
– –
-8,208
Closed -$271K
STTK icon
85
Shattuck Labs
STTK
$646M
– –
-3,709,072
Closed -$75.6M
ALPN
86
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-7,001
Closed -$75K
NGM
87
CALL
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-245,000
Closed -$5M
MRTX
88
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-464,298
Closed -$82.1M
FMTX
89
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-90,141
Closed -$2.09M
ODT
90
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-3,727,261
Closed -$10.8M
DRNA
91
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-1,249,812
Closed -$25.2M
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2021 Portfolio in Review

As of Q4 2021, EcoR1 Capital held 91 positions worth $3.14B, up 9.2% from $2.87B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $471M of net new capital in Q4 2021, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Nurix Therapeutics, an estimated $24.8M trimmed.

  • EcoR1 Capital's largest Q4 2021 buy was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.
  • EcoR1 Capital added most to Protagonist Therapeutics in Q4 2021, an estimated $37.8M increase.
  • EcoR1 Capital's biggest Q4 2021 reduction was Nurix Therapeutics, cutting an estimated $24.8M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2021, selling an estimated $82.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $3.14B portfolio in Q4 2021.
  • EcoR1 Capital opened 20 new positions and closed 15 in Q4 2021.
  • EcoR1 Capital's portfolio value rose 9.2% quarter-over-quarter to $3.14B.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.